The identification of MAPK-pathway activating driver mutations in BRAF, NRAS, KIT, GNAQ and GNA11 in melanoma has revolutionized the treatment of this disease beyond standard chemotherapy to include targeted, small-molecule inhibitors such as vemurafenib, dabrafenib, imatinib, nilotinib and trametinib. This evidence concerns the gene BRAF and melanoma.